← Back to Search

Cancer Vaccine

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) for Kidney Cancer

Phase 1 & 2
Waitlist Available
Led By David Avigan, MD
Research Sponsored by Beth Israel Deaconess Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial is testing the safety of a new cancer vaccine made from a patient's own tumor cells and dendritic cells (a type of white blood cell). The vaccine will be given with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), which helps the body produce white blood cells. Researchers want to see if the vaccine is safe and causes any side effects.

Eligible Conditions
  • Kidney Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Adverse Events Associated With Vaccination With Mature DC/Tumor Fusion and GM-CSF
Secondary outcome measures
To Determine if Cellular and Humoral Immunity is Induced by Serial Vaccination With DC/Tumor Fusion Cells and GM-CSF
to Correlate Immunologic Response Following Vaccination.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2Experimental Treatment2 Interventions
Patients treated with DC/RCC vaccine to evaluate response
Group II: Cohort 1Experimental Treatment2 Interventions
Patients treated with DC/RCC vaccine to evaluate for treatment-limiting toxicity
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
2004
Completed Phase 2
~40
Dendritic Cell Tumor Fusion Vaccine
2004
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor
837 Previous Clinical Trials
13,010,234 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,663 Previous Clinical Trials
40,925,867 Total Patients Enrolled
Dana-Farber Cancer InstituteOTHER
1,079 Previous Clinical Trials
340,948 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
David Avigan 2004. "Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00458536.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top